The latest price target for Amedisys (NASDAQ:AMED) was reported by Deutsche Bank on July 31, 2024. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 3.53% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Amedisys (NASDAQ:AMED) was provided by Deutsche Bank, and Amedisys downgraded their hold rating.

The last upgrade for Amedisys Inc happened on March 1, 2022 when UBS raised their price target to $168. UBS previously had a sell for Amedisys Inc.

The last downgrade for Amedisys Inc happened on July 31, 2024 when Deutsche Bank changed their price target from $101 to $101 for Amedisys Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on July 31, 2024 so you should expect the next rating to be made available sometime around July 31, 2025.

While ratings are subjective and will change, the latest Amedisys (AMED) rating was a downgraded with a price target of $101.00 to $101.00. The current price Amedisys (AMED) is trading at is $97.56, which is out of the analyst’s predicted range.